Bio-Techne (TECH) SVP Shane Bohnen Receives RSU Awards

What Happened

• Shane Bohnen, SVP and General Counsel of Bio-Techne (TECH), was granted two awards of restricted stock units (transaction code A) on August 17, 2026: 11,344 RSUs and 18,432 RSUs, for a total of 29,776 RSUs. The reported acquisition price is $0.00 (typical for RSU grants); these are derivative awards rather than open-market purchases or sales.

Key Details

• Transaction date and price: 2026-08-17; acquisition price $0.00 (award).
• Total RSUs granted: 29,776 (11,344 + 18,432).
• Vesting (from filing footnotes):
  • The 11,344 RSUs: 3,781 RSUs vest on 8/17/2027, 3,781 on 8/17/2028, and 3,782 on 8/17/2029 (footnote F11).
  • The 18,432 RSUs: vest on 8/17/2029 (footnote F12).
  • Each RSU represents a contingent right to receive one share of Bio-Techne common stock (footnote F6).
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Filing: Form 4 filed 2026-08-19 reporting the 8/17/2026 grants; this appears to be a timely Form 4 (no late-filing flag shown).

Context

• These were compensation awards (RSUs) — not purchases or sales. RSUs convert to actual shares only when they vest per the schedule above, so they do not immediately change public float until settlement.
• RSU grants are commonly used for retention and alignment with shareholder value; they are not direct endorsements to buy or sell the stock.